Renovaro Biosciences Inc. (RENB)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
0.81
-0.09 (-10.01%)
At close: Jan 14, 2025, 3:59 PM
0.78
-4.20%
Pre-market Jan 15, 2025, 08:12 AM EST
undefined% (undefined)
Bid | 0.78 |
Market Cap | 129.24M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.98 |
PE Ratio (ttm) | -0.83 |
Forward PE | n/a |
Analyst | n/a |
Ask | 0.84 |
Volume | 313,335 |
Avg. Volume (20D) | 1,083,957 |
Open | 0.94 |
Previous Close | 0.90 |
Day's Range | 0.79 - 0.94 |
52-Week Range | 0.40 - 5.25 |
Beta | undefined |
About RENB
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatme...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2018
Employees 25
Stock Exchange NASDAQ
Ticker Symbol RENB
Website https://www.renovarobio.com
3 months ago ·
Source
+32.01%
Renovaro shares are trading higher. The company ap...
Unlock content with
Pro Subscription
11 months ago ·
Source
-42.86%
Renovaro Biosciences shares are trading lower after Hindenburg Research issued a report on the company and said it has taken a short position in the stock.